{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-005586","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.448956+00:00","generated_at":"2026-06-20T11:54:38.370972+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bicycle Therapeutics increases change-in-control severance for CEO, CFO, and CTO","bullets":["CEO Kevin Lee receives 24 months' base salary and benefits on change-of-control termination; subject to shareholder approval.","CFO Lee Kalowski and CTO Michael Skynner get 18 months' base salary and benefits on change-of-control termination.","Compensation committee approved amendments on Jan 17, 2023; CEO amendment pending AGM vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-005586","json":"https://secwatch.observer/filing/0001104659-23-005586.json","markdown":"https://secwatch.observer/filing/0001104659-23-005586.md","text":"https://secwatch.observer/filing/0001104659-23-005586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923005586/0001104659-23-005586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923005586/tm234142d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:54:38.370972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}